{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T08:29:46Z","timestamp":1648888186538},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T00:00:00Z","timestamp":1524528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00108-018-0427-0","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T07:51:47Z","timestamp":1524556307000},"page":"544-550","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prim\u00e4r bili\u00e4re Cholangitis \u2013 etablierte und neue Therapien"],"prefix":"10.1007","volume":"59","author":[{"given":"M.","family":"Vetter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,24]]},"reference":[{"key":"427_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1741-2358.2000.00067.x","volume":"17","author":"DW Banting","year":"2000","unstructured":"Banting DW, Papas A, Clark DC et\u00a0al (2000) The effectiveness of 10\u202f% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. Gerodontology 17:67\u201376","journal-title":"Gerodontology"},{"key":"427_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/ncpgasthep0521","volume":"3","author":"U Beuers","year":"2006","unstructured":"Beuers U (2006) Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3:318\u2013328","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"427_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jhep.2015.06.031","volume":"63","author":"U Beuers","year":"2015","unstructured":"Beuers U, Gershwin ME, Gish RG et\u00a0al (2015) Changing nomenclature for PBC: from \u201ccirrhosis\u201d to \u201ccholangitis\u201d. J\u00a0Hepatol 63:1285\u20131287","journal-title":"J Hepatol"},{"key":"427_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers U, Trauner M, Jansen P, Poupon R (2015) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J\u00a0Hepatol 62:25\u2013S37","journal-title":"J Hepatol"},{"key":"427_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","volume":"144","author":"M Carbone","year":"2013","unstructured":"Carbone M, Mells GF, Pells G et\u00a0al (2013) Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 144:560\u2013569","journal-title":"Gastroenterology"},{"key":"427_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N et al (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48:871\u2013877","journal-title":"Hepatology"},{"key":"427_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2011.03.031","volume":"56","author":"C Corpechot","year":"2012","unstructured":"Corpechot C, Gaouar F, Chr\u00e9tien Y et\u00a0al (2012) Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J\u00a0Hepatol 56:218\u2013224","journal-title":"J Hepatol"},{"issue":"1","key":"427_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0168-8278(17)30442-7","volume":"66","author":"C Corpechot","year":"2017","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A et al (2017) A\u00a02\u2011year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso). J\u00a0Hepatol 66(1):89","journal-title":"J\u00a0Hepatol"},{"key":"427_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"Deutsche Gesellschaft f\u00fcr Gastroenterologie","year":"2017","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (federf\u00fchrend), Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche M. Crohn\/Colitis ulcerosa Vereinigung (DCCV) et al (2017) Practice guideline autoimmune liver diseases\u2014AWMF-Reg. No.\u00a0021-27. Z\u00a0Gastroenterol 55:1135\u20131226","journal-title":"Z Gastroenterol"},{"key":"427_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield GM, Beuers U, Corpechot C et\u00a0al (2017) EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J\u00a0Hepatol 67:145\u2013172","journal-title":"J Hepatol"},{"key":"427_CR11","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","volume":"68","author":"AE Kremer","year":"2008","unstructured":"Kremer AE, Beuers U, Oude-Elferink RP, Pusl T (2008) Pathogenesis and treatment of pruritus in cholestasis. Drugs 68:2163\u20132182","journal-title":"Drugs"},{"key":"427_CR12","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C et\u00a0al (2015) Development and validation of a\u00a0scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 149:1804\u20131812","journal-title":"Gastroenterology"},{"key":"427_CR13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","volume":"117","author":"M Leuschner","year":"1999","unstructured":"Leuschner M, Maier K\u2011P, Schlichting J et al (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a\u00a0prospective double-blind trial. Gastroenterology 117:918\u2013925","journal-title":"Gastroenterology"},{"key":"427_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/hep.26365","volume":"58","author":"GF Mells","year":"2013","unstructured":"Mells GF, Pells G, Newton JL et al (2013) Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 58:273\u2013283","journal-title":"Hepatology"},{"key":"427_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.21472","volume":"45","author":"M Nakamura","year":"2007","unstructured":"Nakamura M, Kondo H, Mori T et al (2007) Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45:118\u2013127","journal-title":"Hepatology"},{"key":"427_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G et al (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N\u00a0Engl J Med 375:631\u2013643","journal-title":"N Engl J Med"},{"key":"427_CR17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"RE Poupon","year":"1997","unstructured":"Poupon RE, Lindor KD, Cauch-Dudek K et al (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113:884\u2013890","journal-title":"Gastroenterology"},{"key":"427_CR18","volume-title":"FDA adds boxed warning to highlight correct dosing of ocaliva (obeticholic acid) for patients with a\u00a0rare chronic liver disease","author":"Research C for DE and Drug Safety and Availability","year":"2017","unstructured":"Research C for DE and Drug Safety and Availability (2017) FDA adds boxed warning to highlight correct dosing of ocaliva (obeticholic acid) for patients with a\u00a0rare chronic liver disease. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm594941.htm\n                    \n                  . Zugegriffen: 20. Febr. 2018"},{"key":"427_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14579","author":"GJ Webb","year":"2018","unstructured":"Webb GJ, Rahman SR, Levy C, Hirschfield GM (2018) Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a\u00a0cross-disease cohort study. Aliment Pharmacol Ther. \n                    https:\/\/doi.org\/10.1111\/apt.14579","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0427-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T19:05:26Z","timestamp":1556046326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0427-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,24]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0427-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,24]]},"assertion":[{"value":"24 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.E.\u00a0Kremer erhielt Vortragshonorare von Bristol-Myers Squibb, Falk Foundation, Intercept und MSD und hat Beratungsvertr\u00e4ge mit Beiersdorf, GSK, Intercept und MSD gezeichnet. M.\u00a0Vetter gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}